Devyser Diagnostics AB

DVYSR · Nasdaq Stockholm · Healthcare

54.80SEK +7.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: −61.4%

Performance

1 month

−8.1%

1 year

−61.4%

3 years, per year

−6.4%

5 years, per year

–

Largest fall, 3 years

−68.0%

Below the peak now

−65.3%

Volatility, 1 year

47.7%

Return with dividends reinvested.

Key figures

P/E

58.1

P/B

2.3

Dividend yield

0.0%

Return on equity

+4.0%

Net margin

+6.1%

Market value

92 m USD

Quality, value and trend

Where Devyser Diagnostics stands against every Nordic stock today. 100 is best.

Quality85

Profitability and a sound balance sheet over time. Better than 85% of Nordic stocks.

Value29

The price measured against earnings, assets and cash flow. Better than 29% of Nordic stocks.

Trend12

The price development over the past year. Better than 12% of Nordic stocks.

Combined32

Quality, value and trend together. Better than 32% of Nordic stocks.

About Devyser Diagnostics

Devyser Diagnostics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 110 employees.

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis